The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension

Journal of Hypertension

Volumn 17, Issue 1, 1999, Pages 129-136

  Hedner, Thomas ^a   Himmelmann, Anders ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin II receptor antagonist; Dosage regimen; Efficacy; Eprosartan; Essential hypertension; Tolerance

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; EPROSARTAN; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 0033052755     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917010-00019     Document Type: Article

References (15)

1. Brunner RH, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286:441-449.
2. Griending KK, Murphy TK, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87:1816-1828.
3. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension: a dozen years of experience. Arch Intern Med 1994; 154:513-523.
4. Johnston C. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346:1403-1407.
5. Hedner T, Samuelsson D, Lunde H, Lindholm L, Andren L, Wiholm BE. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1992; 304:941-946.
6. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992; 117:234-242.
7. Lunde H, Hedner T, Samuelsson D, Lotvall J, Andren L, Lindholm L, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994; 308:18-21.
8. Hedner T, Himmelmann A. Eprosartan, an angiotensin II type 1 receptor antagonist. Pharmacology and clinical use in hypertension. Cardiovasc Drug Rev 1998 (in press).
9. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role of cardiovascular diseases. Can J Cardiol 1995; 11 (suppl F):13F-19F.
10. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80:219-227.
11. Hedner T, Falk M. Physician and patient evaluation of hypertension-related risks and benefits from treatment. Blood Press 1997; 6 (Suppl):26-34.
12. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153:154-183.
13. Zanchetti A, Chalmers J, Arakawa K, Gyarfas I, Hamet P, Hansson L, et al. The 1993 guidelines for the management of mild hypertension. Memorandum from a WHO/ISH meeting. Blood Press 1993; 2:86-100.
14. Zannad F. Practical relevance of the 24-h trough: peak ratio of antihypertensive drugs. J Hypertens 1995; 13 (Suppl 2):S109-S112.
15. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens 1996; 18:463-472